Roche unit accused of stepping on D&I pledge with lawsuit

Roche unit Spark Therapeutics (STI) is pursuing a “misguided” lawsuit that contravenes its stated mission to combat systemic racism, according to gene therapy developer Bluebird Bio.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Novartis to sell Roche shares back for $20.7 billion

5 November 2021 Novartis yesterday, November 4, announced that it is selling its entire stake in Roche—equating to 53.3 million bearer shares—back to the Swiss healthcare company for the sum of $20.7 billion.

Big Pharma

Amgen asks SCOTUS to reject Roche petition

14 April 2021 Amgen subsidiary Immunex has asked the US Supreme Court not to review a Federal Circuit decision that found the company did not patent the same rheumatoid arthritis invention twice.

Big Pharma

Amgen and Roche target Samsung’s Bioepis in patent suit

1 May 2019 Amgen and Roche have filed a joint patent infringement claim against Samsung’s biopharmaceutical company Bioepis.

More on this story

Big Pharma

Novartis to sell Roche shares back for $20.7 billion

Big Pharma

Amgen asks SCOTUS to reject Roche petition

14 April 2021 Amgen subsidiary Immunex has asked the US Supreme Court not to review a Federal Circuit decision that found the company did not patent the same rheumatoid arthritis invention twice.

Big Pharma

Amgen and Roche target Samsung’s Bioepis in patent suit

1 May 2019 Amgen and Roche have filed a joint patent infringement claim against Samsung’s biopharmaceutical company Bioepis.

More on this story

Big Pharma

Novartis to sell Roche shares back for $20.7 billion

Big Pharma

Amgen asks SCOTUS to reject Roche petition

14 April 2021 Amgen subsidiary Immunex has asked the US Supreme Court not to review a Federal Circuit decision that found the company did not patent the same rheumatoid arthritis invention twice.

Big Pharma

Amgen and Roche target Samsung’s Bioepis in patent suit

1 May 2019 Amgen and Roche have filed a joint patent infringement claim against Samsung’s biopharmaceutical company Bioepis.